Table 1.
TAHOD and AHOD participant baseline characteristics at ART initiation
| Characteristics | TAHOD (n = 3221) | AHOD (n = 147) | Total (n = 3368) | |
|---|---|---|---|---|
| Sex | Male | 2267 (70.4) | 135 (91.8) | 2402 (71.3) |
| Female | 954 (29.6) | 12 (8.2) | 966 (28.7) | |
| Age (years) | Median (IQR) | 36 (31, 43) | 42 (35, 50) | 37 (31, 43) |
| BMI (kg/m2) | Median (IQR) | 21.2 (19.1, 23.6) | 24.2 (21.7, 26.6) | 21.3 (19.1, 23.7) |
| Unknown | 784 (24.3) | 75 (51) | 859 (25.5) | |
| Race | Caucasian | 7 (0.2) | 128 (87.1) | 135 (4.0) |
| Asian | 3194 (99.2) | 9 (6.1) | 3203 (95.1) | |
| Others | 20 (0.6) | 1 (0.7) | 21 (0.6) | |
| Unknown | 0 (0) | 9 (6.1) | 9 (0.3) | |
| Mode of HIV acquisition | Heterosexual | 2039 (63.3) | 19 (12.9) | 2058 (61.1) |
| MSM | 953 (29.6) | 114 (77.6) | 1067 (31.7) | |
| PWID | 100 (3.1) | 8 (5.5) | 108 (3.2) | |
| Other | 129 (4.0) | 3 (2.0) | 132 (3.9) | |
| Unknown | 0 (0) | 3 (2.0) | 3 (0.1) | |
| Family history of ASCVD | Yes | 212 (6.6) | 13 (8.8) | 225 (6.7) |
| Smoking status | Never | 1997 (62.0) | 59 (40.1) | 2056 (61.0) |
| Former | 555 (17.2) | 37 (25.2) | 592 (17.6) | |
| Current | 669 (20.8) | 51 (34.7) | 720 (21.4) | |
| Diabetes mellitus | Yes | 40 (1.2) | 2 (1.4) | 42 (1.2) |
| CD4 cell count (cells/μL) | Median (IQR) | 222 (110, 359) | 380 (245, 542) | 228 (112, 369) |
| Systolic blood pressure (mmHg) | Median (IQR) | 120 (110, 130) | 124 (114, 130) | 120 (110, 130) |
| Fasting total cholesterol (mmol/L) | Median (IQR) | 4.8 (4.0, 5.5) | 4.9 (4.2, 5.6) | 4.8 (4.0, 5.6) |
| HDL-cholesterol (mmol/L) | Median (IQR) | 1.2 (1.0, 1.4) | 1.1 (1.0, 1.4) | 1.2 (1.0, 1.4) |
| Current PI use | Yes | 378 (11.7) | 55 (37.4) | 433 (12.9) |
| Atazanavir | Yes | 114 (3.5) | 11 (7.5) | 125 (3.7) |
| Lopinavir | Yes | 136 (4.2) | 4 (2.7) | 140 (4.2) |
| Current NRTI use | Yes | 3156 (98.0) | 132 (89.8) | 3288 (97.6) |
| Tenofovir | Yes | 912 (28.3) | 46 (31.3) | 958 (28.4) |
| Abacavir | Yes | 310 (9.6) | 16 (10.9) | 326 (9.7) |
| Current INSTI use | Yes | 53 (1.6) | 19 (12.9) | 72 (2.1) |
| Raltegravir | Yes | 26 (0.8) | 4 (2.7) | 30 (0.9) |
| Dolutegravir | Yes | 16 (0.5) | 11 (7.5) | 27 (0.8) |
| Current NNRTI use | Yes | 2607 (80.9) | 54 (36.7) | 2661 (79.0) |
| Efavirenz | Yes | 1496 (46.4) | 30 (20.4) | 1526 (45.3) |
| Nevirapine | Yes | 1100 (34.2) | 20 (13.6) | 1120 (33.3) |
| Five-year primary ASCVD riska | <5% | 3079 (95.6) | 139 (94.5) | 3218 (95.6) |
| 5%–9.9% | 123 (3.8) | 6 (4.1) | 129 (3.8) | |
| ≥10% | 19 (0.6) | 2 (1.4) | 21 (0.6) | |
| HIV RNA viral load (copies/mL) | Median (IQR) | 84 315 (23 700, 252 045) | 27 943 (807, 125 541) | 82 564 (21 400, 245 995) |
| Unknown | 1173 (36.4) | 27 (18.4) | 1194 (35.5) |
Values are n (% total) unless otherwise indicated.
aBased on the D:A:D risk equation.